Save on Talimogene Laherparepvec with Coupons, Discounts & Savings Programs

Talimogene Laherparepvec is available as a 106(1 million) PFU per mL, 108
(100 million) PFU per mL in single-use vial.

Talimogene Laherparepvec is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Talimogene Laherparepvec is viral therapy that is injected directly into melanoma tumors. There, it multiplies inside the cancer cells and destroys them.

The ecommended starting dose is up to a maximum of 4 mL of Talimogene Laherparepvec at a concentration of 106 (1 million) plaque-forming units (PFU) per mL. Subsequent doses should be administered up to 4 mL of Talimogene Laherparepvec at a concentration of 108  (100 million) PFU per mL into the lesion.

Talimogene Laherparepvec is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication if you are pregnant or immunocompromised.

Common side effects of Talimogene Laherparepvec:

• Fatigue
• Chills
• Fever
• Nausea
• Influenza-like illness
• Injection site pain

Serious side effects are rare with Talimogene Laherparepvec. Tell your doctor right away if you get any of the signs and symptoms of herpes
infection, including but not limited to:

• Pain, burning, tingling, or blister formation around the mouth, genitals, or any part of the body, near or far from the injection site
• Eye pain, light sensitivity, discharge from the eyes, or blurry vision
• Weakness in arms or legs
• Extreme drowsiness (feeling sleepy)
• Mental confusion

The following medications may interact with Talimogene Laherparepvec:

• Talimogene Laherparepvec is sensitive to acyclovir. Acyclovir or other antiherpetic viral agents may interfere with the effectiveness of Talimogene Laherparepvec. No drug interaction studies have been conducted with Talimogene Laherparepvec

Various FDA-approved generic manufacturers

Talimogene Laherparepvec may harm your unborn baby. You should not become pregnant during treatment with Talimogene Laherparepvec. Talk to your healthcare provider about effective birth control methods.

• Imlygic